An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease. HBV affects ...
Hepatitis B affects almost 300 million people worldwide, according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor Viread ...
Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi. The articles, information, and ...
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2024.. Total fourth quarter 2024 revenue increased 6% to $7.6 billion compared to the same period ...
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results